Compare CRNT & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNT | ABOS |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.1M | 182.0M |
| IPO Year | 2000 | 2021 |
| Metric | CRNT | ABOS |
|---|---|---|
| Price | $2.66 | $2.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 539.1K | 292.3K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.11 | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $0.99 |
| 52 Week High | $2.84 | $3.60 |
| Indicator | CRNT | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 51.64 |
| Support Level | $2.30 | $2.24 |
| Resistance Level | $2.82 | $2.77 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 65.52 | 66.41 |
Ceragon Networks Ltd is a wireless transport specialist, providing wireless connectivity solutions to markets globally across various industries, including wireless (mobile) network service providers and private networks, enabling them to build new networks and evolve networks towards 4G and 5G services. Its portfolio mainly comprises the IP-20 and IP-50 product series, including integrated multi-technology radio units operating across frequencies from 4 GHz to 86 GHz, as well as single-radio devices used for wireless data transport. Additionally, the company offers turnkey services including: network and radio planning, site survey, installation, network auditing and optimization, and more. Geographically, it derives maximum revenue from India, followed by North America and other regions.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.